Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG
Ryan L. Steinberg(University of Iowa), Michael A. O’Donnell(University of Iowa Health Care), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), M. Eric Hyndman(University of Calgary), Sarah L. Mott(University of Iowa Holden Comprehensive Cancer Center), Trafford Crump(University of Calgary), Donald L. Lamm(The University of Texas System), Kenneth G. Nepple(University of Iowa), Nathan A. Brooks(Eli Lilly (United States)), Lewis J. Thomas(Washington University in St. Louis), Trinity J. Bivalacqua(University of Pennsylvania), Vignesh T. Packiam(Rutgers, The State University of New Jersey), Jonathan Wang(Beth Israel Deaconess Medical Center), William C. DeWolf(Beth Israel Deaconess Medical Center), Max Kates(Duke Medical Center), Andrew Vitale(University of Iowa)
Cited by 31
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Priapism: Pathogenesis, Epidemiology, and Management
|The Journal of Sexual Medicine|2010|401
RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction
|Proceedings of the National Academy of Sciences|2004|316